The USPTO has published a new patent application (US20260091016A1) claiming a therapeutic composition comprising at least three specific molecules: chrysin, pinocembrin, and CAPE. The application asserts the mixture is for use in preventing or treating neuroinflammation and diseases or disorders associated with neuroinflammation. Inventors are Jérémie Lavaur and Nicolas Cardinault. This A1 publication represents the formal public disclosure of the patent claims after 18 months from the earliest effective filing date.

This publication does not create compliance obligations or deadlines. Competitors developing flavonoid-based neuroinflammation therapies should monitor the prosecution of this application to assess potential freedom-to-operate implications. The scope and strength of any resulting patent rights will be determined during examination. No action is required at this stage, as this is an application publication rather than an issued patent.